Venture Capital Partners
DEEPLAB maintains strategic relationships with leading venture capital firms that focus on biotech and healthcare innovations:
— Chan Zuckerberg Initiative (CZI) — Invests in scalable, impact-driven companies across science, education, and health, including ventures like Citizen Health and the CZ Biohub Network.
— Flagship Pioneering — Known for creating and funding groundbreaking biotech companies, including Moderna, with a focus on integrating AI into drug discovery.
— ARCH Venture Partners — Invests in early-stage biotech firms, supporting the commercialization of innovative technologies.
— Versant Ventures — Manages over $4 billion in assets, backing companies like CRISPR Therapeutics and Gritstone bio.
— Third Rock Ventures — Focuses on building transformative biotech companies from the ground up.
— OrbiMed — One of the largest investment firms dedicated to the healthcare sector, supporting companies across all stages.
— Atlas Venture — Specializes in early-stage biotech investments, fostering innovation in therapeutics.
— New Enterprise Associates (NEA) — Invests in a broad range of healthcare startups, providing both capital and strategic support.
— Domain Associates — Focuses on healthcare investments, particularly in pharmaceuticals and medical devices.
— Canaan Partners — Invests in early-stage healthcare companies, supporting their growth and development.
— Astellas Venture Management — The venture arm of Astellas Pharma, investing in innovative therapeutic technologies.
— Amgen Ventures — Supports early-stage biotech companies aligned with Amgen’s strategic interests.
— Bristol Myers Squibb (BMS) Ventures — Invests in companies developing innovative therapies in areas of strategic interest to BMS.
— Eli Lilly Ventures — Focuses on early-stage investments in biotechnology and healthcare companies.
— BioGeneration Ventures — Provides early-stage funding for European life sciences companies, supporting their growth and innovation.
— General Catalyst — Invests in transformative healthcare companies, aiming to redefine venture capital in the sector.
— Cathay Innovation — Launched a $1 billion AI-focused venture fund to support global AI companies in digital health and other sectors.
Grant and Non-Dilutive Funding Partners
DEEPLAB also collaborates with various grant organizations to provide non-dilutive funding opportunities:
— National Institutes of Health (NIH) SEED Fund — Supports early-stage biomedical startups through SBIR/STTR grants, fostering innovation in health technologies.
— National Science Foundation (NSF) Biological Technologies Program — Offers grants for startups developing cutting-edge biological technologies.
— Biomedical Advanced Research and Development Authority (BARDA) — Provides funding for advanced research and development of medical countermeasures.
— Congressionally Directed Medical Research Programs (CDMRP) — Funds high-impact research in various medical fields, supporting innovative projects.
— Advance Biotech Grant Program (Sigma-Aldrich/Merck) — Recognizes and supports emerging biotech startups with products, services, and consultation.
— Alliance for Cancer Gene Therapy (ACGT) — Funds biotech companies working on cell and gene therapy projects for difficult-to-treat cancers.
